PRME

Conviction 14HealthcareScan · Thu, Sep 24, 2026

Prime Medicine, Inc. (PRME) closed at $3.07 (-1.92%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 44, RS Rating 13, -54.0% from its 52-week high, -13.0% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

PRME$3.07-1.92%

ResistanceSupportVol 14

Vol MA14 3.12M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Prime Medicine, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.primemedicine.com ↗

Price3.07

Change-1.92%

Gap-1.44%

Rel volume1.57×

Avg volume2.88M

Avg $ vol9.61M

SMA 203.38

SMA 503.24

SMA 2003.52

Price vs 50-5.14%

Price vs 200-12.72%

MA stackbearish

50/200 cross—

Supertrenddown · 3.81

RSI (14)44

MACD hist-0.03

MACD cross—

Stoch %K / %D15 / 34

ADX (14)16

+DI / −DI22 / 20

RSI divergence—

MACD divergence—

ATR %8.22%

ADR %6.87%

52w high6.67

52w low2.70

From 52w high-53.97%

Above 52w low+13.70%

New 52w highNo

SqueezeOff

Bollinger width28.87%

%B0.19

Donchian pos15.05%

Donchian high3.86

Donchian low2.93

AVWAP (52w high)3.82

vs AVWAP high-19.59%

AVWAP (52w low)3.41

vs AVWAP low-9.95%

OBV trendDown

Chaikin MF (20)0.04

Today vs 20d1.57×

Avg vol (14d)3.12M

Avg vol (20d)2.88M

Avg $ vol (20d)9.61M

Market cap556.83M

RS Rating13 / 99

RS 3m (vs SPY)-7.95%

RS 6m (vs SPY)-32.24%

RS line new highNo

Trend template0/8

Technical rank22.3

1 week-2.23%

1 month-17.25%

3 months-3.46%

6 months-15.43%

1 year-43.04%

YTD-13.03%

P/E-2.77

P/B13.99

P/S120.21

P/FCF-3.33

EPS-1.35

Div yield—

ROE-505.27%

ROA-80.77%

Debt/Eq—

Current3.05

EV/EBITDA-2.53

Gross margin—

Net margin—

Rev growth55.28%

EPS growth-2.69%

Price target7.67

Target upside149.84%

Analyst ratingBuy

Institutional55.47%

Ent. value509.38M

Revenue1.23M

Net income-42.11M

Gross profit—

Free cash flow-167.09M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out180.62M

Employees146

ListedThu, Oct 20, 2022

Free float69.86M

Float %38.7%

Short interest36.76M

Days to cover13.1d

Short volume38.6%

Squeeze score73 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.24 vs −$0.24

Last surprise0.0% beat

Setup gradeD

Conviction14 / 100

Pattern quality—

Tech rank22.3 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.79

Support2.83

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PRME

All disclosures →

No recent disclosed trades by Congress in PRME. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PRME

Insider	Side	Shares	Value	Traded	Filed
Foster-Cheek Kaye I Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Kelly Michael Aaron Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
NELSEN ROBERT Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Cahill Thomas Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Schenkein David P Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Chung Wendy Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Marrazzo Jeffrey D Director · Stock Option (right to buy) · 2026-06-05	Grant	75K	$0	2026-06-05	2026-06-08
Makhni Svetlana Ni Chief Financial Officer · Stock Option (right to buy) · 2026-04-16	Grant	800K	$0	2026-04-16	2026-04-17

SEC filings

EDGAR filings in PRME · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.